SCHEMBL1407684

SCHEMBL1407684

O=C(O)CCc1ccc(Nc2cccc(-c3c4cccc(C(F)(F)F)c4nn3Cc3ccccc3)c2)cc1

nearest known ligand 0.61

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 15/20 0.61
NR1H3 Q13133 15/20 0.61
SYK P43405 2/20 0.45
NR1I2 O75469 2/20 0.42
NR3C1 P04150 2/20 0.42
AR P10275 1/20 0.42
RXRA P19793 1/20 0.42
PTGDR2 Q9Y5Y4 1/20 0.42
PPARG P37231 1/20 0.41
PPARD Q03181 1/20 0.41
PPARA Q07869 1/20 0.41
RHOA P61586 1/20 0.41
FFAR1 O14842 1/20 0.41
FFAR4 Q5NUL3 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1407891 0.95 NR1H2 (0.63) NR1H2NR1H3SYKNR1I2NR3C1
SCHEMBL1407555 0.93 NR1H2 (0.66) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407635 0.92 NR1H2 (0.62) NR1H2NR1H3SYKNR1I2NR3C1
SCHEMBL1408136 0.91 NR1H2 (0.63) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL27730726 0.90 NR1H2 (0.61) NR1H2NR1H3SYKNR1I2NR3C1
SCHEMBL1407442 0.89 NR1H2 (0.77) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407889 0.88 NR1H2 (0.66) NR1H2NR1H3SYKNR1I2NR3C1
SCHEMBL1407801 0.87 NR1H2 (0.60) NR1H2NR1H3SYKNR1I2NR3C1
SCHEMBL27730678 0.87 NR1H2 (0.60) NR1H2NR1H3SYKNR1I2NR3C1
SCHEMBL3859671 0.86 NR1H2 (0.58) NR1H2NR1H3NR1I2NR3C1AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592363-B2 Indazoles WYETH (US) 2009-09-22 US claimed
CN-101213194-A Indazoles useful in treating cardiovascular diseases WYETH CORP (US) 2008-07-02 CN claimed
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases WYETH (US) 2006-02-09 US claimed
EP-2295429-A1 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases Wyeth LLC (US) 2011-03-16 EP disclosed
US-7592363-B2 Indazoles WYETH (US) 2009-09-22 US disclosed
CN-101213194-A Indazoles useful in treating cardiovascular diseases WYETH CORP (US) 2008-07-02 CN disclosed
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases WYETH (US) 2006-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases NR1H2, NR1H3, CYP46A1 NR1H2 1/4885NR1H3 2/4885SYK 3422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.